topotecan has been researched along with Chemotherapy-Induced Febrile Neutropenia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barron, R; Chandler, DB; Fust, K; Li, X; Lyman, GH; Maschio, M; Parthan, A; Walli-Attaei, M; Weinstein, MC | 1 |
1 other study(ies) available for topotecan and Chemotherapy-Induced Febrile Neutropenia
| Article | Year |
|---|---|
Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Chemotherapy-Induced Febrile Neutropenia; Cost-Benefit Analysis; Docetaxel; Drug Costs; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Markov Chains; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Taxoids; Topotecan | 2014 |